ObsEva S.A.
OBSN.SW
Swiss Exchange0.00
CHF
+0.00
- -
ObsEva S.A.
OBSN.SW
(Swiss Exchange)
Recent
price
0.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- ObsEva S.A. ObsEva SA (OBSN.SW) is a Swiss-based clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for women's reproductive health and pregnancy, including conditions such as uterine fibroids, endometriosis, preterm labor, and infertility; its core pipeline features linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for uterine fibroids and endometriosis-associated pain, nolasiban (OBE001), an oral oxytocin receptor antagonist to improve IVF success rates and pregnancy outcomes, and ebopiprant, a former EP4 receptor antagonist for preterm labor that was out-licensed and subsequently returned. Founded in 2012 by Ernest Loumaye and André Chollet and headquartered in Geneva, Switzerland, the company previously held dual listings on NASDAQ (OBSV) and the SIX Swiss Exchange before delisting from both amid financial challenges. ObsEva targets global markets with a focus on areas of high unmet need in women's health, leveraging in-licensed assets from strategic partnerships. In recent major developments within the last two years, ObsEva announced a strategic reorganization in February 2023 to consolidate operations in Switzerland, preserve cash, and prioritize nolasiban development including a planned Phase 1b trial; recovered full worldwide rights to nolasiban in July 2023 after termination of a prior license; saw Organon return rights to ebopiprant in October 2023; applied for a moratorium in November 2023 and received a temporary court-granted moratorium in January 2024 to facilitate pivotal deals; updated its board and leadership changes in March 2024; delisted from the SIX Swiss Exchange effective May 2024; and initiated wind-down of operations in February 2024 due to insufficient resources for audited 2023 financials, suspending certain reporting obligations.